4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Free Cash Flow of -$68.1 million for Q1 2026, down 42.23% year-over-year from -$117.9 million in Q1 2025, and down 333.65% quarter-over-quarter from $29.2 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Free Cash Flow data on file, last reported at -$68.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$68.1 million, down 42.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$129.3 million (up 15.59% YoY), and the FY2025 annual result was -$109.1 million, up 19.25% from the prior year.
- Free Cash Flow retreated to -$68.1 million in Q1 2026 per FDMT's latest filing, from $29.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $29.2 million in Q4 2025 and troughed at -$68.1 million in Q1 2026.
- A 5-year average of -$28.1 million and a median of -$28.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow sank 10748.17% in 2024, then soared 166.97% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$22.9 million in 2022, then retreated by 18.47% to -$27.1 million in 2023, then tumbled by 60.79% to -$43.5 million in 2024, then soared by 166.97% to $29.2 million in 2025, then tumbled by 333.65% to -$68.1 million in 2026.
- Business Quant data shows FDMT's Free Cash Flow at -$68.1 million in Q1 2026, $29.2 million in Q4 2025, and -$46.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -68.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.13 Mn |
| Mar 31, 2026 | -68.13 Mn |
| Dec 31, 2025 | 29.16 Mn |
| Dec 31, 2025 | 29.16 Mn |
| Sep 30, 2025 | -46.41 Mn |
| Sep 30, 2025 | -46.41 Mn |
| Jun 30, 2025 | -43.93 Mn |
| Jun 30, 2025 | -43.93 Mn |
| Mar 31, 2025 | -47.90 Mn |
| Mar 31, 2025 | -47.90 Mn |
| Dec 31, 2024 | -43.54 Mn |
| Dec 31, 2024 | -43.54 Mn |
| Sep 30, 2024 | -32.05 Mn |
| Sep 30, 2024 | -32.05 Mn |
| Jun 30, 2024 | -29.71 Mn |
| Jun 30, 2024 | -29.71 Mn |
| Mar 31, 2024 | -29.80 Mn |
| Mar 31, 2024 | -29.80 Mn |
| Dec 31, 2023 | -27.08 Mn |
| Dec 31, 2023 | -27.08 Mn |